ELI Lilly AND Company (LLY) stock
ELI Lilly AND Company is a growth company in the “Health care” sector. Here are the key numbers from official filings and the price. The full report with 20 years of history, comparison and news is in the Analyst.
| Metric | Value | Verdict |
|---|---|---|
| Revenue growth a year | 13.3% | moderate |
| Profit margin | 31.7% | high |
| Debt to annual profit | 1.3 | small |
| Dividends a year | 0.5% | small |
| Price to earnings (P/E) | 50 | expensive |
| Share price over the year | +37% | rose |
The full report: 20 years of history, valuation, comparison with any companies, news and a live price.
Open the LLY report →In short
Of five key metrics, 4 are strong and 1 weak. Over the past year the stock rose (+37%).
Which goal it fits
- Grow capital — partly.
- Earn income — partly.
- Preserve — fits.
Assessed by the same rules as in the Analyst: the company's metrics are checked against what matters for each goal.
Does ELI Lilly AND Company pay dividends
Yes. The dividend yield is about 0.5% a year at the current price. The dividend has been raised 10 years in a row.
Is ELI Lilly AND Company stock expensive
Price to earnings (P/E) is 50: an investor pays 50 dollars for each dollar of the company's annual profit. That is expensive: future growth is already priced in.
Other companies in the sector
Johnson & Johnson · AbbVie · Merck · Astrazeneca · Amgen · Gilead Sciences · Abbott Laboratories · Novo Nordisk A/S · Pfizer · Intuitive Surgical
Worth reading
How to pick a stock: five metrics · What an ETF is in plain words · How to start investing from zero
Data as of 2026-10-06: filings — SEC EDGAR, price — Yahoo Finance. This page is educational and is not investment advice.